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Heterogenous nuclear ribonucleoprotein (hnRNP) A1 is an alterna-
tive splicing factor that is mainly nuclear, although it shuttles
rapidly between nuclear and cytoplasmic compartments. Cells
stressed by osmotic shock (OSM) activate the mitogen-activated
protein kinase kinase3/6-p38 signaling pathway, which in turn
results in accumulation of hnRNP A1 in the cytoplasm. This effect
modulates alternative splicing regulation in vivo and correlates
with increased hnRNP A1 phosphorylation. We have characterized
the molecular mechanism involved in the cytoplasmic accumula-
tion of hnRNP A1 in NIH 3T3 cells subjected to OSM. This treatment
results in serine-specific phosphorylation within a C-terminal pep-
tide, dubbed the ‘‘F-peptide,’’ which is adjacent to the M9 motif
that mediates bidirectional transport of hnRNP A1. Analysis of
mutants in which the F-peptide serines were replaced by aspartic
acids or alanines showed that F-peptide phosphorylation is re-
quired for the subcellular redistribution of hnRNP A1 in cells
subjected to OSM. Furthermore, F-peptide phosphorylation mod-
ulates the interaction of hnRNP A1 with transportin Trn1. Our
findings suggest that the phosphorylation of F-peptide by cell-
signaling pathways regulates the rate of hnRNP A1 nuclear import.
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Heterogenous nuclear ribonucleoprotein (hnRNP) plays animportant role in all of the steps of mRNA metabolism (1,
2). The human hnRNP family consists of at least 24 members,
which are among the most abundant nuclear proteins (3, 4).
hnRNP A1, a member of the hnRNP AB subfamily, has been
studied extensively and participates in the regulation of tran-
scription, splicing, and mRNA export.
hnRNP A1 binds RNA through two RNA recognition motif
modules at its N terminus (amino acids 1–196). The C-terminal
domain (amino acids 197–320) comprises several RGG repeats,
which also contribute to RNA binding. The C terminus also
includes a 38-aa sequence, the M9 motif (amino acids 268–305),
that is involved in hnRNP A1 nuclear import and export (5–8).
Although at steady state hnRNP A1 is predominantly nuclear, it
shuttles rapidly between the nucleus and cytoplasm (9). The
shuttling of hnRNP A1 is subject to regulation and is thought to
play a role in cell proliferation, survival, and differentiation of
normal and transformed cells (10). The shuttling of hnRNP A1
also is required for normal myelopoiesis and BCRABL leuke-
mogenesis (10).
The molecular mechanism that regulates the nuclear export of
hnRNP A1 is unknown. In contrast, the mechanism of hnRNP
A1 nuclear import is better understood. Two transport receptors
of the karyopherin- family, Trn1 and Trn2b, interact directly
with the M9 sequence and mediate hnRNP A1 import (11–13).
hnRNP A1 transport requires an intact M9 motif, and a single
amino acid change, G274A, abolishes both import and export of
the protein (14).
The subcellular distribution of hnRNP A1 is the result of
steady-state control of its transport between the nucleus and the
cytoplasm. However, it is not clear whether the nuclear accu-
mulation of hnRNP A1 is caused by its nuclear retention or
rather is a consequence of a faster rate of nuclear import,
compared with its export to the cytoplasm. The former hypoth-
esis is supported by experiments in early mouse embryos showing
that nascent transcripts are required to localize hnRNPA1 in the
nucleus (15). Moreover, inhibition of RNA polymerase II with
actinomycin D results in accumulation of hnRNP A1 in the
cytoplasm (9). On the other hand, studies of hnRNPA1 shuttling
by a heterokaryon assay showed that its nuclear import is faster
than its export (9).
The localization of hnRNPs also is regulated by posttransla-
tional modifications. In budding yeast, the arginine methyl
transferase Hmt1p methylates Npl3p and Hrp1p (two hnRNP
proteins) and is essential for their export from the nucleus (16).
In mammals, hnRNP A1 undergoes several modifications, e.g.,
methylation, sumoylation, ubiquitination, and phosphorylation
(17–21). In vivo, four arginine residues (R193, R205, R217, and
R224) within the RGG repeats of hnRNP A1 are methylated.
This modification is thought to be constitutive and stoichiomet-
ric in HeLa cells and to influence the RNA-binding properties
of the RGG repeats (17, 22). A single hnRNP A1 peptide
(comprising S199) was characterized as an in vitro substrate of
PKC- and PKA kinases (20, 23). Overexpression of either
kinase increases the cytoplasmic level of hnRNP A1 (20, 23).
Endogenous hnRNP A1 is only very weakly phosphorylated in
cells grown under normal conditions (21). However, we showed
previously that osmotic shock (OSM) treatment of cells induces
cytoplasmic accumulation of hnRNP A1, concomitant with an
increase in its phosphorylation (21). We therefore proposed that
specific phosphorylationmight play a role in the regulation of the
hnRNP A1 nucleocytoplasmic distribution.
Here, we show that mammalian cells subjected to OSM exhibit
an increase in serine-specific phosphorylation of hnRNP A1. We
mapped the site(s) of phosphorylation to the C-terminal domain,
between amino acids 301 and 318, a segment dubbed the
‘‘F-peptide.’’ Mutation of the serines in the F-peptide to aspartic
acids, mimicking a hyperphosphorylated state, resulted in accu-
mulation of hnRNP A1 in the cytoplasm, even without OSM. In
contrast, mutation of all of the F-peptide serines to alanines
abolished OSM-induced phosphorylation of hnRNP A1 and
resulted in its nuclear retention. Furthermore, we found that
OSM weakens the interaction between hnRNP A1 and Trn1. In
vitro and in vivo assays of transportin interactions with hnRNP
A1 mutant proteins suggest that hnRNP A1Trn1 binding is
negatively regulated by OSM-induced phosphorylation. Thus,
the cytoplasmic accumulation of phosphorylated hnRNP A1 in
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cells stressed by OSM probably results from its impaired nuclear
import.
Materials and Methods
Plasmids. The mammalian expression plasmid pCGT-A1 carries
a T7-tagged version of hnRNP A1 (24). The F1 and F2 mutants
were generated by PCR and inserted into the pCGT plasmid
(XbaI–BamHI) by using the following reverse primers: F1
(5-ccatcgggatccTTAAAATCTTCTGCCgtcGCCATAatcgtcatcg-
tcatcgtcACCGCCATAGCCACCTTGGTTTCGTGG-3) and F2
(5-ccatcggaattcTTAAAATCTTCTGCCagcGCCATAtgcagcgg-
cagctgcggcACCGCCATAGCCACCTTGGTTTCGTGG-3).
Plasmids expressing GST fusions to hnRNP A1, or to the F1 and
F2 mutants, were generated by PCR and subcloning into the
pGex-5 1 vector (AmershamPharmacia). The hnRNPA1 cDNA
was inserted into the BamHI site, and the F1 and F2 mutants were
inserted between the BamHI and EcoRI sites. All constructs were
verified by sequencing.
[32P]-Labeling, Phosphoamino Acid Analysis, and Immunoprecipita-
tion. For metabolic labeling, 500 Ciml (1 Ci  37 GBq) 32Pi
was used per 60-mm dish of proliferating NIH 3T3 cells. The cells
were preincubated in phosphate-depleted medium for 1 h before
addition of 32Pi. OSM involved addition of 600 mM sorbitol for
3 h. Cell lysates were made with RIPA buffer (0.15 MNaCl0.05
M TrisHCl, pH 7.21% Triton X-1001% sodium deoxy-
cholate0.1% SDS) containing 10 gml leupeptin and aproti-
nin, 1 mM PMSF, 0.25 mM orthovanadate, 20 mM -glycero-
phosphate, and 10 mM sodium fluoride. Endogenous proteins
were immunoprecipitated with mAbs 4B10 (hnRNP A1), MC3
(U2AF65), or 7–53 [protein phosphatase 2C (PP2C)] (46).
The 4B10 and MC3 antibodies were kindly provided by G.
Dreyfuss (University of Pennsylvania School of Medicine, Phil-
adelphia) and J. Valca´rcel (Centre for Genomic Regulation,
Barcelona), respectively (25, 26). The immunoprecipitated pro-
teins were separated by SDSPAGE and transferred onto a
polyvinylidene difluoride membrane. Detection of hnRNP A1
byWestern blotting was with mAbA155, which recognizes both
hnRNP A1 and its isoform A1B (L. Manche and A.R.K.,
unpublished data). Phosphoamino acid analysis was done by
using the method of Kamps (http:pingu.salk.edusefton
HyperprotocolsPaa.html).
Cell Fractionation. Nuclear and cytoplasmic extracts were pre-
pared from four 60-mm dishes of NIH 3T3 cells at 60%
confluence. The cells were collected by scraping in PBS plus 1
mM EDTA and spun at 250  g for 5 min at 4°C. The packed
cells were resuspended in six volumes of buffer A (10 mMHepes,
pH 7.950 mM NaCl0.5 M sucrose0.1 mM EDTA0.5%
Triton X-1001 mM DTT17.5 mM -glycerophosphate100
mM sodium fluoride10g/ml leupeptin4g/ml aprotinin) and
incubated on ice for 5 min. The cells were centrifuged at 230 
g for 10 min, and the supernatant (cytoplasmic extract) was
cleared by centrifugation at 15,300  g for 15 min. The pellet
(nuclei) was washed with six volumes of buffer B (10 mM
Hepes10 mMKCl0.1 mM EDTA0.1 mM EGTA1 mMDTT
plus protease inhibitors) and spun in a swinging-bucket centri-
fuge at 160  g for 5 min. The nuclei were resuspended in four
volumes of buffer C (10 mM Hepes500 mM NaCl0.1 mM
EDTA0.1 mM EGTA0.1% Nonidet P-401 mM DTT plus
protease inhibitors), and the nuclear proteins were extracted by
vortexing at 4°C for 15 min. The nuclear extract was clarified by
centrifugation at 15,300 g for 10 min. The cytoplasmic fraction
and nuclear extract were adjusted to 10% (volvol) glycerol and
frozen at 80°C.
MALDI-TOF MS. hnRNP A1 was immunoprecipitated with a mix of
mAbs 4B10 and 9H10 (25) and analyzed by SDSPAGE. The gel
was stained with GelCode Blue Stain Reagent (Pierce), and the
band corresponding to hnRNP A1 was excised for in-gel trypsin
digestion. The digests were concentrated, and the resulting
peptides were mixed with -cyano-4-hydroxycinnamic acid
and analyzed by MALDI-TOF MS (Voyager-DE RP, Applied
Biosystems). The spectral data were analyzed by using the
PROFOUND search engine (27).
Purification of GST Recombinant Proteins and Pull-Down and Co-
immunoprecipitation Assays. GST fusion proteins were expressed
in Escherichia coli BL21 and purified on glutathione-Sepharose
beads (Amersham Pharmacia). Each purified protein was dia-
lyzed against buffer D [20 mM Hepes-KOH, pH 8.0100 mM
KCl0.2 mM EDTA20% (vol/vol) glycerol0.5 mM PMSF1
mM DTT)]. [35S]methionine-labeled Trn1 was synthesized by
using the plasmid pET28b-Trn1 (kindly provided by Rui-Ming
Xu, Cold Spring Harbor Laboratory) and a coupled reticulocyte
lysate system (TNT T7, Promega). For protein-binding assays, 2
g of GST recombinant protein was incubated for 15 min at 4°C
with 15 l of glutathione-Sepharose in 500 l of binding buffer
[20 mM PBS, pH 7.41% (vol/vol) Triton1 mM PMSF]. The
beads were washed twice with binding buffer and once with
buffer E [20 mM Hepes, pH 7.9250 mM KCl0.05% (vol/vol)
Nonidet P-40100 g/ml BSA1 mM PMSF]. The beads were
incubated with 4 l of [35S]methionine-labeled Trn1 in 250 l of
buffer E for 1 h at 4°C, washed three times for 15 min in buffer
E, and boiled in SDSPAGE sample buffer. The bound proteins
were separated by SDSPAGE, and the labeled Trn1 was
detected by using autoradiography and quantitated by using a
phosphorimager (BAS2000, Fuji).
Immunofluorescence Microscopy. Immunofluorescence micros-
copy was carried out as described in ref. 21. HeLa cells were
transfected by electroporation with plasmids expressing T7-
tagged proteins and cultured on glass coverslips. At 24–36 h
posttransfection, cells were either left untreated or exposed to
600 mM sorbitol for 2.5 h, fixed with 4% p-formaldehyde in PBS
for 30 min, and permeabilized with 0.2% Triton X-100 for 5 min.
The T7-tagged proteins were detected as described in ref. 24.
Immunoprecipitation and Immunoblotting. To analyze the interac-
tion between Trn1 and hnRNP A1, cytoplasmic fractions from
control or stressed HeLa cells were prepared as described in
ref. 33. Cells were resuspended in RSB100 (10 mM TrisHCl,
pH 7.42.5 mM MgCl2100 mM NaCl) containing 35 gml
digitonin, 10 mM -glycerophosphate, 10 mM NaF, and a
protease inhibitor mixture (Roche). The suspension was in-
cubated on ice for 5 min and disrupted by repeated passage
through 25-gauge needles. Centrifugation at 4,000  g for 15
min yielded a cytoplasmic supernatant fraction. Endogenous
or T7-tagged hnRNP A1 and mutants were immunoprecipi-
tated from this fraction by incubation for 15 min at 4°C with
mAb 4B10 linked to protein A-Sepharose beads. After exten-
sive washing with RSB100, the bound fraction was eluted by
boiling in SDSPAGE sample buffer. Equivalent amounts of
immunoprecipitated hnRNP A1 proteins were separated by
SDSPAGE, transferred to a polyvinylidene dif luoride mem-
brane, and probed with the following antibodies: 4B10
(1:10,000) and D45 (1:1,000) from BD Transduction Labora-
tories, anti-T7 tag (1:1,000) from Novagen, or anti-
phosphoserine (1:100) from Abcam (Cambridge, U.K.).
Results
OSM Induces Serine-Specific Phosphorylation of hnRNP A1. We pre-
viously demonstrated by using immunofluorescence microscopy
that NIH 3T3 cells subjected to OSM in 600 mM sorbitol
undergo cytoplasmic mislocalization of endogenous hnRNP A1
(21). To address what fraction of the endogenous hnRNP A1
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relocalizes in response to OSM stress, we performed cell frac-
tionation at different time points after OSM treatment and
analyzed the distribution of hnRNP A1 in nuclear and cytoplas-
mic extracts (Fig. 1A). Western blot analysis showed a shift of
hnRNP A1 from the nuclear to the cytoplasmic fractions, in
agreement with our immunofluorescence results described in
ref. 21. Furthermore, 90% of hnRNP A1 was detected in the
nucleus without OSM treatment (Fig. 1A, lane 1), whereas
50% accumulated in the cytoplasm after 120 min of OSM
treatment (Fig. 1A, lane 5). Therefore, this stress stimulus has a
major effect on the endogenous hnRNP A1 pool.
The cytoplasmic accumulation of hnRNP A1 in OSM-treated
cells correlates with an increase in its phosphorylation (21). We
have now determined the specificity of this phosphorylation. We
compared hnRNP A1 phosphorylation with that of two other
nuclear mRNA-processing factors, PP2C- and U2AF65, which
can be immunoprecipitated from cell lysates (26, 28, 46). Phos-
phorylation of hnRNP A1 was greatly enhanced in OSM-treated
cells, whereas PP2C- and U2AF65 were unaffected (data not
shown). Both hnRNP A1 and U2AF65 are shuttling proteins (9,
28), whereas PP2C- is nuclear (46). Therefore, OSM-induced
phosphorylation does not target all shuttling or nuclear splicing
factors.
To identify which residues undergo OSM-induced phosphor-
ylation, we performed phosphoamino acid analysis of [32P]-
labeled hnRNP A1 immunopurified from treated or untreated
cells. Our 2D chromatography of equal amounts of hydrolyzed
protein showed that hnRNP A1 is phosphorylated on serine
under both conditions (Fig. 1B). OSM treatment resulted in a
strong increase in the level of serine phosphorylation, and no
radioactivity was detected corresponding to either phospho-
threonine or phosphotyrosine.
Identification of hnRNP A1 Phosphopeptide (F-Peptide) in OSM-
Treated Cells. To map the OSM-specific phosphorylation site(s),
we used MALDI-TOF and compared the spectra of hnRNP A1
purified from untreated vs. OSM-treated cells to detect post-
translationally modified peptides. Theoretically, trypsin diges-
tion of hnRNP A1 can produce 39 peptides, 14 of which have
sizes that can be detected byMALDI-TOF. In practice, however,
we recovered only seven peptides after exhaustive trypsin diges-
tion of immunopurified hnRNP A1, accounting for 22% of the
hnRNP A1 sequence (Fig. 2A). Among the missing peptides,
four cannot be generated by trypsin digestion because of hnRNP
A1 arginine methylation in HeLa cells at positions R193, R205,
R217, and R224 (17, 29, 30). Methylated arginines are not
cleaved by trypsin, resulting in larger peptides that are not
detected by MALDI-TOF. In cells treated by OSM, we found an
additional peptide corresponding to an extreme C-terminal
fragment of hnRNP A1 (amino acids 301–319, F-peptide) that,
according to its mass, underwent posttranslational modification
with covalent addition of four phosphates and one methyl group.
Moreover, we also detected a shorter, unmodified version of the
F-peptide (amino acids 301–318) in OSM samples, suggesting
that at least two forms of hnRNP A1, with and without modi-
fication of the F-peptide, are present in OSM-treated cells. The
F-peptide comprises six consecutive serines (S308–S313), an
additional serine (S316), and two consecutive arginines (R318
and R319). We conclude that four of the seven serines and
almost certainly one of the two arginines are modified by
phosphorylation and methylation, respectively. The MALDI-
TOF analysis does not allow us to determine the precise four
serine residues that undergo phosphorylation, and it is possible
that there is heterogeneity in terms of which of the six consec-
utive serines undergo modification. On the other hand, given
that trypsin cleaved after R319 to generate the modified F-
peptide, we conclude that R318 is the likely site of arginine
methylation. Alignment of the C-terminal protein sequences
from several hnRNP A1 orthologs (Fig. 2B) shows that both the
M9 and F-peptide sequences are highly conserved in vertebrates.
Serines Within F-Peptide Are Involved in Localization and Phosphor-
ylation of hnRNP A1. To determine whether there is a functional
link between OSM-induced cytoplasmic accumulation of
hnRNP A1 and phosphorylation of serines in the F-peptide, we
Fig. 1. Subcellular distribution and specific phosphorylation of hnRNP A1 in
cells subjected to OSM. (A) Nuclear (NE) and cytoplasmic (CE) extracts were
prepared from NIH 3T3 cells treated with 600 mM sorbitol for the indicated
times. The distribution of endogenous hnRNP A1 was detected by Western
blotting with mAb A155 by using a 4-fold excess of CE over NE total protein.
(B) Phosphoamino acid analysis of metabolically labeled hnRNP A1 by 2D
electrophoresis after immunoprecipitation from cells treated with OSM or
untreated. Equal amounts of hnRNP A1 (estimated by Ponceau red staining)
were excised, quantitated by Cerenkov counting (indicated for each condi-
tion), and processed for phosphoamino acid analysis. The positions of phos-
phoserine (P-Ser), phosphotyrosine (P-Tyr), or phosphothreonine (P-Thr) stan-
dards are shown as dotted circles. *, Partially digested peptides.
Fig. 2. hnRNP A1 peptides identified by MALDI-TOF. (A) The identified
peptides are listed with their coordinates in the 320-aa hnRNP A1 sequence.
The positions of the seven peptides also are shown as black bars over a
diagram of the hnRNP A1 protein, and the modified F-peptide is shown as a
gray bar. The four black dots represent the methylated arginines R193, R205,
R217, and R224. (B) Comparative alignment of the M9 sequence (268–305) and
the F-peptide (301–319). The C termini of several vertebrate hnRNP A1 or-
thologs were aligned by using CLUSTALW (www.ebi.ac.ukclustalw). Residues
identical in all four species are highlighted.
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generated two mutant versions of hnRNP A1 in which all of the
serines in the F-peptide were replaced either by aspartic acids
(mimicking phosphorylation) or alanines (preventing phosphor-
ylation) (Fig. 3A). HeLa cells were transfected with T7-tagged
versions of wild-type or mutant hnRNP A1 cDNAs, followed by
immunofluorescence detection of the tagged proteins to deter-
mine their subcellular localization (Fig. 3B). T7-tagged wild-type
hnRNP A1, as a control, exhibited the same subcellular distri-
bution in OSM cells as observed for endogenous hnRNP A1 in
ref. 21; OSM resulted in cytoplasmic accumulation of T7-hnRNP
A1 in 72% of transfected cells. The mutant mimicking consti-
tutive phosphorylation of the F-peptide (F1 mutant) localized in
the cytoplasm, even without OSM treatment. However, this
effect was only observed in 48% of the transfected cells and
increased after OSM treatment (to 82%), which may reflect
competition with endogenous hnRNP A1 for binding to cyto-
plasmic transportin. In contrast, mutation of the serines to
alanines (F2 mutant) strongly inhibited the OSM effect on
hnRNP A1 localization, because only 11% of the transfected
cells accumulated the F2 mutant protein in the cytoplasm.
Our data showed that phosphorylation of the F-peptide was
sufficient for the cytoplasmic accumulation of hnRNP A1 even
in the absence of stress stimuli, although the effect was seen in
a reduced percentage of transfected cells (48% vs. 82%; see
below). We suggest two possible explanations for this effect
not being quantitative. First, MS did not provide full-sequence
coverage of hnRNP A1, so there might be additional OSM-
induced phosphorylation site(s) and partial functional redun-
dancy between these sites. Second, other events besides phos-
phorylation also might modulate hnRNP A1 localization. To
address the first possibility, we immunoprecipitated hnRNP
A1 and the F2 mutant version from OSM-treated and un-
treated cells and measured their phosphoserine level (Fig. 4).
The T7-tagged hnRNP A1 behaved in the same manner as
endogenous hnRNP A1 (compare Figs. 1B and 4, lanes 2 and
3) and showed increased phosphorylation in cells subjected to
OSM. In contrast, the F2 mutant remained hypophosphory-
lated even after OSM treatment (Fig. 4, lanes 4 and 5). Thus,
the F-peptide is the main site of hnRNP A1 phosphorylation
during OSM. We conclude that other mechanisms besides
hnRNP A1 phosphorylation also might contribute to the
extent of OSM-induced relocalization of the protein, which
will require further investigation.
Hyperphosphorylation of F-Peptide Reduces the Interaction of hnRNP
A1 with Transportin. Next, we investigated the molecular mecha-
nism by which hnRNP A1 accumulates in the cytoplasm of
stressed cells. hnRNPA1 transport depends on theM9 sequence,
which serves both as a nuclear import and export signal, and
mediates the interaction of hnRNPA1 with transportin Trn1 (11,
12). To test whether OSM affects this interaction, endogenous
hnRNP A1 was immunoprecipitated from treated or untreated
cells, and the presence of Trn1 in the pellet was detected by
Western blotting (Fig. 5). The amount of coimmunoprecipitated
Trn1 was greatly reduced in OSM-treated cells (Fig. 5A, lanes 1
and 2). This effect was not caused by OSM-induced Trn1
degradation, because equal amounts of Trn1 were present in cell
lysates before immunoprecipitation (Fig. 5A, lanes 4 and 5). We
conclude that hnRNP A1 has reduced affinity for Trn1 in
OSM-treated cells.
Because OSM changed the extent of F-peptide phosphoryla-
tion, we tested whether this effect, in turn, influences the
interaction between hnRNP A1 and Trn1. To this end, we
performed in vitro binding assays between wild-type or mutant
hnRNP A1 fused to GST and in vitro-translated [35S]-Trn1. Trn1
interacted specifically with GST-hnRNP A1 (Fig. 6A, lane 1) but
not with GST alone (Fig. 6A, lane 2) or GST-PP2C (Fig. 6A,
lane 6), which has a classical bipartite nuclear localization signal
and no homology with the M9 sequence. The GST-F1 mutant
Fig. 3. Localization of transfected wild-type or mutant hnRNP A1. (A) The
domain structure of T7-tagged hnRNP A1 and F1F2 mutants is shown sche-
matically. The mutations of serines (S308–S313 and S316) to aspartic acids (F1)
or alanines (F2) in the F-peptide are shown. (B) Immunofluorescence micro-
graphs showing the localization of T7-hnRNP A1, T7-F1, and T7-F2 in HeLa
cells, with or without OSM treatment for 2.5 h. The tabulated data indicate the
percentage of transfected cells in which the tagged proteins accumulated in
the cytoplasm. Approximately 500 cells were counted for each condition.
Fig. 4. Mutation of the F-peptide’s seven serines to alanines abolishes the
increase of hnRNP A1 phosphorylation in cells subjected to OSM. HeLa cells
were transfected with T7-hnRNP A1 or T7-F2 plasmids and treated with OSM
for 3 h. The transiently expressed proteins were immunoprecipitated from
total protein lysates by using a T7-tag mAb and separated by SDSPAGE. The
levels of serine phosphorylation and immunoprecipitated proteins were de-
termined by Western blotting with anti-phosphoserine and anti-T7 antibod-
ies, respectively.
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mimicking phosphorylation of the F-peptide reduced the binding
to [35S]-Trn1 (Fig. 6A, lane 3), whereas the affinity of GST-F2
for Trn1 was similar to that of GST-hnRNP A1 (Fig. 6A, lanes
1 and 4).
We further assayed the coimmunoprecipitation of Trn1 with
transiently expressed versions of hnRNP A1, F1, and F2 from
cytoplasmic lysates. T7-tagged hnRNP A1 behaved as endoge-
nous hnRNP A1, and its interaction with Trn1 decreased in cells
treated with OSM (compare Fig. 6B, lanes 1 and 2, with Fig. 5,
lanes 1 and 2). As expected, the T7-F1 mutant had lower affinity
for Trn1 than did wild-type hnRNP A1, and OSM did not affect
its interaction with Trn1 (Fig. 6B, lanes 3 and 4). On the other
hand, the interaction of the F2 mutant with Trn1 in untreated
cells was comparable to that of wild-type T7-hnRNP A1, but it
did not change after OSM (Fig. 6B, lanes 5 and 6). The GST
pull-down and coimmunoprecipitation experiments gave quali-
tatively consistent results, although the effect of the F1 mutation
was stronger by the second assay; this quantitative difference
may reflect the different nature of the assays, although the lack
of methylation of hnRNP A1 expressed in bacteria also might
play a role. Taken together, these results demonstrate that
although the F-peptide is distinct from the M9 sequence, its
hyperphosphorylation regulates hnRNP A1 binding to Trn1.
Discussion
The regulation of gene expression by cell-signaling pathways has
largely focused on transcription factors. However, some factors
involved in mRNA processing, such as hnRNPK and hnRNPA1,
also are subject to regulation by cell-signaling pathways (21, 31).
The polypyrimidine tract-binding proteinhnRNP I is a substrate
for phosphorylation by PKA, and the phosphorylation state
likewise controls the nuclearcytoplasmic distribution of the
protein (32). Similarly, changes in calcium concentration leading
to hyperphosphorylation of Tra21 result in its relocalization to
the cytoplasm (33). We reported in ref. 21 that cells stressed by
OSM activate the mitogen-activated protein kinase kinase
(MKK)3/6-p38 signaling pathway, resulting in an altered subcel-
lular distribution of hnRNP A1. Here, we have characterized the
molecular mechanism responsible for this redistribution. We
found that OSM induces phosphorylation of hnRNP A1 within
a stretch of serine residues in a tryptic peptide (F-peptide),
resulting in a decreased interaction of hnRNP A1 with its import
receptor, transportin. We propose that hyperphosphorylation of
the F-peptide reduces the rate of hnRNP A1 nuclear import.
The shuttling activity of hnRNP A1 requires the M9 sequence
(7, 14), which mediates its interaction with Trn1 and Trn2b
(11–13, 34). Transportins also are import receptors for other
proteins that lack homology to M9 (34–37). Thus, it is thought
that transportin recognizes each import substrate through sec-
ondary andor tertiary structural features, rather than primary
sequence (34). Our results suggest that phosphorylation of the
F-peptide affects the binding of M9 to Trn1 and decreases
hnRNP A1 nuclear import. The M9 sequence alone does not
have the same affinity and specificity for transportin as full-
length hnRNPA1 (13). Taken together, these results suggest that
the F-peptide may affect structural features of the M9Trn
interaction. Because the F-peptide and the M9 motif are juxta-
posed near the C terminus of hnRNP A1 (Fig. 2B), we propose
that the extent of F-peptide phosphorylation regulates the
accessibility of M9. For example, the interaction surface of M9
may be masked by phosphorylated F-peptide, or a conforma-
tional change in M9 may reduce its affinity for Trn1. At present,
the structure of the C-terminal domain of hnRNP A1 remains
unknown.
hnRNP A1 regulation by phosphorylation has not been ex-
tensively studied in vivo, because it is difficult to detect the low
steady-state level of phosphorylated protein or protein that is
phosphorylated only under certain conditions. The character-
ization of F-peptide as an in vivo phosphorylation site in hnRNP
A1 is a step toward the understanding of hnRNP A1 regulation
by OSM-activated signaling pathways. The next step will be the
identification of the kinase(s) responsible for this modification.
We have already reported that p38 does not directly phosphor-
ylate hnRNP A1 (21). Other kinases known to phosphorylate
hnRNP A1 in vitro or in vivo, such as PKA, casein kinase II, and
PKC (20, 23, 38), are not part of the MKK3/6-p38 signaling
cascade. However, PKC andor PKA can induce cytoplasmic
localization of hnRNP A1, so cells treated with OSM may
activate these kinases to regulate the hnRNPA1 interaction with
transportin. As a part of the process of identifying the relevant
hnRNP A1 kinase(s), it is of interest to determine whether the
F-peptide is phosphorylated in the nucleus or in the cytoplasm.
We have compared the phosphorylation of hnRNP A1 in
cytoplasmic and nuclear extracts prepared from cells subjected
to OSM and observed increased phosphorylation in the cyto-
Fig. 5. Decreased association of hnRNP A1 with Trn1 in OSM-stressed cells.
hnRNP A1 was immunoprecipitated from cytoplasmic extracts with mAb 4B10.
The immunoprecipitated proteins were separated by SDSPAGE, and Trn1 and
hnRNP A1 were detected by Western blotting with D45 and 4B10 antibodies,
respectively. In the panels on the right, 120th of the amount of each protein
extract used for immunoprecipitation was analyzed as a control for protein
expression level.
Fig. 6. Hyperphosphorylation of F-peptide reduced the interaction of hnRNP
A1 with Trn1. (A) The indicated GST recombinant proteins were bound to
gluthatione-Sepharose and assayed for binding to in vitro-translated [35S]-
Trn1; The proteins were analyzed by SDSPAGE (Coomassie blue; Lower), and
[35S]-Trn1 was detected by using autoradiography ([35S]-Trn1; Upper). (B) T7
plasmids expressing hnRNP A1 or F1F2 mutants were transfected into HeLa
cells, and the transiently expressed proteins were immunoprecipitated from
total protein lysates with a T7-tag mAb. The T7-tagged proteins and the
coimmunoprecipitated endogenous Trn1 were detected by Western blotting
with T7 and D45 antibodies, respectively. A fraction of the total protein lysate
(140th of input) also was analyzed to determine the level of endogenous Trn1
expressed under each condition.
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plasmic extracts (data not shown). However, the specificity of
this phosphorylation and the link between the kinase(s) and the
MKK3/6-p38 signaling pathway will require further study.
In addition to F-peptide phosphorylation, we also have found
a new site of arginine methylation in hnRNPA1, R318 (Fig. 2A).
This methylation event was detected only in hnRNP A1 isolated
from cells treated by OSM, suggesting that it is an OSM-specific
posttranslational modification. It is currently unknown whether
or not methylation and phosphorylation of F-peptide are co-
regulated. In Saccharomyces cerevisiae, methylation of hnRNP
proteins was proposed to regulate their nuclear export (16). An
attractive hypothesis is that OSM-specific methylation enhances
the nuclear export of hnRNP A1, whereas phosphorylation
impairs its nuclear import. This possibility might explain our
observation that the F1 and F2 mutations did not affect hnRNP
A1 localization in 100% of the cells. However, by using MS, we
did not find peaks corresponding to F-peptide modified only by
either methylation (R318) or serine phosphorylation, suggesting
that if these modification states do exist, they may be highly
transitory. On the other hand, we cannot exclude the possibility
that the longer transit time of hnRNP A1 in the cytoplasm of
OSM-treated cells may indirectly increase its methylation, be-
cause an arginine methylase specific for hnRNP A1 is present in
the cytoplasm (39). The first model seems more attractive, but
further study will be required to distinguish between these two
possibilities.
hnRNP A1 is involved in pre-mRNA splicing regulation as an
antagonist of SR proteins, and hnRNP A1 regulation by the
MKK3/6-p38 signaling pathway affects the control of alternative
splice-site selection in vivo (21). However, it is not known
whether OSM also affects the activity of SR proteins. Although
we have shown that two members of this protein family (SF2
ASF and SC35) remain in the nucleus in cells treated by OSM
(21), it is possible that OSM nevertheless affects their phosphor-
ylation and shuttling activity. The interaction between SR pro-
teins and import receptors is modulated by phosphorylation
(40–42). In addition, at least two SR proteins (SF2ASF and
9G8) are exported to the cytoplasm in a hypophosphorylated
state (43, 44). Thus, an increase of SR protein phosphorylation
may inhibit their nuclear export andor increase their nuclear
import rate. Finally, SF2ASF was recently shown to be involved
in translation regulation (45). By analogy, it will be interesting to
determine whether hnRNP A1 in cells subjected to OSM has a
distinct activity when bound to cytoplasmic mRNA.
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